Complex regional pain syndrome (CRPS), formerly known as reflex sympathetic dystrophy syndrome (RSDS), is a chronic pain condition that usually affects an extremity. It causes intense pain, swelling, and changes in the skin in the affected area. CRPS usually develops after an injury, a surgery, a stroke or a heart attack. It disproportionately affects those who have had fractures, sprains or crushing injuries. The affected area may feel like it’s burning, stinging or experiencing sharp pain.
Market key trends:
The key driver propelling the growth of the complex regional pain syndrome market is the development and launch of novel therapeutic agents for effective management of CRPS symptoms. For instance, in March 2021, NervoMedic announced positive results from a phase 1 clinical study evaluating the safety and efficacy of NT-1654 in patients with CRPS. NT-1654 is a novel intranasal formulation of the neuropeptide molecule Endothelin receptor A (ETA). The study results demonstrated that NT-1654 was safe and well-tolerated, and reduced pain in patients with lower extremity CRPS. This indicates the potential of NT-1654 to serve as an effective treatment option for CRPS pain management. Similarly, ongoing R&D activities to develop other novel therapeutic strategies such as gene therapy, cell therapy and neuromodulation devices are expected to boost the complex regional pain syndrome market growth over the forecast period.
Segment Analysis
The global complex regional pain syndrome market is divided into two key segments based on type and end use. By type, the nerve injury segment held the largest market share in 2024 as nerve injuries are the most common cause of CRPS onset. By end use, the hospitals segment dominated in 2024 as hospitals provide specialized care and advanced treatment options to CRPS patients.
Key Takeaways
Global Complex Regional Pain Syndrome Market Size is expected to witness high growth over the forecast period of 2024-2031. The global Complex Regional Pain Syndrome Market is estimated to be valued at US$ 119.47 Mn in 2023 and is expected to exhibit a CAGR of 7.2% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Regional analysis suggests that North America will retain its position as the fastest growing regional market due to increasing healthcare expenditures and growing incidence of CRPS in the region. This can be attributed to factors such as rising healthcare expenditure, increasing awareness about CRPS diagnosis and treatment, and growing geriatric population in the region which is at a higher risk of developing CRPS.
Key players operating in the complex regional pain syndrome market are Intercos S.p.A., Kolmar Korea Co. Ltd., Scalpi Cosmética sa, Cosmax Inc., Mana Products Inc., KBL cosmetics Ltd., Urist Cosmetics Incorporated, Fareva Holding SA, Milliona Cosmetics Co., Ltd., Skinlys, Maesa SAS, Schwanhäußer Holding GmbH & Co. KG, Tricorbraun Inc., Herrco Cosmetics Limited, Architectural Beauty, Allure Labs Inc., Case Mason Filling, Inc., Pardaco Trading Pte Ltd, and KDC/ONE among others.
Key players operating in the complex regional pain syndrome market are focusing on expansion of their regional presence and new product launches. For instance, Intercos opened a new production plant in India in 2023 to strengthen its presence in the Asia Pacific region. Similarly, Kolmar Korea launched advanced neuromodulation devices for CRPS treatment in 2023. Players are also investing in R&D to develop more effective drugs and therapeutic alternatives for complex regional pain syndrome.
Get More Insights On This Topic: https://www.newswirestats.com/complex-regional-pain-syndrome-market-growth-is-driven-by-rising-cases-of-trauma/
Explore More Article: https://captionssky.com/adhesive-tapes-evolution-and-applications/
Comments
0 comment